These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32733110)

  • 21. Earlier Diagnosis of Tardive Dyskinesia.
    Kremens DE
    J Clin Psychiatry; 2019 Dec; 81(1):. PubMed ID: 31846242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence, clinical correlates and risk factors associated with Tardive Dyskinesia in Chinese patients with schizophrenia.
    Uludag K; Wang DM; Goodman C; Chen DC; Wang L; Zhang X
    Asian J Psychiatr; 2021 Dec; 66():102877. PubMed ID: 34638091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa.
    Patterson BD; Swingler D; Willows S
    Schizophr Res; 2005 Jul; 76(1):89-97. PubMed ID: 15927802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia.
    Xu D; Ham AG; Tivis RD; Caylor ML; Tao A; Flynn ST; Economen PJ; Dang HK; Johnson RW; Culbertson VL
    EBioMedicine; 2017 Dec; 26():132-137. PubMed ID: 29191560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
    Go CL; Rosales RL; Caraos RJ; Fernandez HH
    Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of Blood Biochemical Markers with Tardive Dyskinesia in Schizophrenic Patients.
    Wu Q; Yuan F; Zhang S; Liu W; Miao Q; Zheng X; Lu S; Hou K
    Dis Markers; 2022; 2022():1767989. PubMed ID: 35299866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.
    Morgenstern H; Glazer WM
    Arch Gen Psychiatry; 1993 Sep; 50(9):723-33. PubMed ID: 8102845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tardive dyskinesia: Who gets it and why.
    Frei K
    Parkinsonism Relat Disord; 2019 Feb; 59():151-154. PubMed ID: 30522959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.
    Sachdev P
    Aust N Z J Psychiatry; 2004 Jun; 38(6):445-9. PubMed ID: 15209837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data.
    Preskorn SH; Macaluso M
    J Psychiatr Pract; 2016 Mar; 22(2):117-23. PubMed ID: 27138080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
    J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tardive dyskinesia in psychiatric patients with substance use disorders.
    Olivera AA; Kiefer MW; Manley NK
    Am J Drug Alcohol Abuse; 1990; 16(1-2):57-66. PubMed ID: 1970451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis.
    O'Brien A
    Int J Geriatr Psychiatry; 2016 Jul; 31(7):683-93. PubMed ID: 26679687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients.
    Richardson MA; Haugland G; Craig TJ
    Am J Psychiatry; 1991 Oct; 148(10):1322-8. PubMed ID: 1680296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study.
    Chan CH; Chan HY; Chen YC
    Int Clin Psychopharmacol; 2018 May; 33(3):155-162. PubMed ID: 29324468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinguishing akathisia and tardive dyskinesia: a review of the literature.
    Munetz MR; Cornes CL
    J Clin Psychopharmacol; 1983 Dec; 3(6):343-50. PubMed ID: 6139392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of Tardive Dyskinesia in an Electronic Medical Record Study at a Large Community Mental Health Treatment Center.
    North CS; McDonald K; Hunter J; Burruss J
    Prim Care Companion CNS Disord; 2022 Jun; 24(4):. PubMed ID: 35768015
    [No Abstract]   [Full Text] [Related]  

  • 39. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia.
    Barnes TR; McPhillips MA
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S49-57. PubMed ID: 9690971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia.
    Achalia RM; Chaturvedi SK; Desai G; Rao GN; Prakash O
    Asian J Psychiatr; 2014 Jun; 9():31-5. PubMed ID: 24813033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.